Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial
ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that its open label study evaluating QRX003 as a treatment for Netherton Syndrome has reached 50% enrollment.
The company’s open label study is investigating the safety and efficacy of QRX003 topical lotion in Netherton Syndrome patients who are currently receiving off-label systemic therapy, primarily biologic therapy, and is being conducted under an open Investigational New Drug (IND).
Quoin announced it had dosed the first patient in its clinical trial in March 2023 and has now dosed its fifth patient out of a total of 10 patients that are expected to participate in this single-arm study.
Quoin Pharmaceuticals CEO, Dr. Michael Myers, said, “We are very pleased with the level of interest that our two clinical trials have generated. Reaching 50% enrollment for this, our open label study, is a very significant milestone and an important step forward for Quoin as we pursue the development of a safe and effective treatment for this devastating disease. We anticipate reporting top-line data from this study in the second half of 2023.”
In addition to its open label study, Quoin is conducting a double blinded, vehicle controlled trial assessing two different doses of QRX003 topical lotion versus a vehicle lotion in Netherton Syndrome patients. Both studies are actively recruiting and dosing patients. If proven to be safe and effective, long term daily application of QRX003 could lead to the development of a more normally functioning skin barrier and a significant improvement in the quality of life of Netherton Syndrome patients.
For more information about Quoin’s clinical trials in Netherton Syndrome, please visit: https://www.nethertonsyndromeclinicaltrials.com/
About Quoin Pharmaceuticals Ltd.
About Netherton Syndrome
Cautionary Note Regarding Forward Looking Statements
For further information, contact:
From AMR to AMI: Transforming Legacy Systems with LoRaWAN and Integrating Legacy Meters to the System
Registration Counters Open
Capitalizing on 5G for Revenue Growth